CVRX (CVRx, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CVRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Brent Binkowski | CHIEF OPERATING OFFICER | Buy | — | — |
| 2026-08-13 | Brent Binkowski | CHIEF OPERATING OFFICER | Sell | — | — |
| 2026-06-03 | Mudit K. Jain | Director | A | — | — |
| 2026-06-03 | JOSEPH P SLATTERY | Director | A | — | — |
| 2026-06-03 | Kevin J. Ballinger | Director | A | — | — |
| 2026-06-03 | Kirk G. Nielsen | Director | A | — | — |
| 2026-06-03 | Mitch C. Hill | Director | A | — | — |
| 2026-06-03 | MARTHA SHADAN | Director | A | — | — |
| 2026-06-03 | MICHAEL D DALE | Director | A | — | — |
| 2026-03-16 | Philip B. Adamson | Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | A | — | — |
| 2026-03-03 | Robert Allen John | Chief Revenue Officer | MIXED | — | — |
| 2026-03-03 | Brent Binkowski | CHIEF OPERATING OFFICER | A | — | — |
| 2026-03-03 | Kevin Hykes | PRES & CEO | MIXED | — | — |
| 2026-03-03 | PAUL VERRASTRO | CHIEF MKTG & STRAT OFFICER | MIXED | — | — |
| 2026-03-03 | JARED OASHEIM | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-23 | Mudit K. Jain | Director | Buy | — | — |
| 2026-02-18 | Mudit K. Jain | Director | Buy | — | — |
| 2026-01-08 | Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | Sell | — | — |
| 2025-12-01 | & JOHNSON JOHNSON | 10%+ Owner | Sell | — | — |
| 2025-11-25 | & JOHNSON JOHNSON | 10%+ Owner | Sell | — | — |
| 2025-11-14 | Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | Sell | — | — |
| 2025-11-10 | & JOHNSON JOHNSON | 10%+ Owner | Sell | — | — |
| 2025-08-13 | Brent Binkowski | CHIEF OPERATING OFFICER | A | — | — |
| 2025-06-05 | Mitch C. Hill | Director | A | — | — |
| 2025-06-05 | JOSEPH P SLATTERY | Director | A | — | — |
| 2025-06-05 | Mudit K. Jain | Director | A | — | — |
| 2025-06-05 | MARTHA SHADAN | Director | A | — | — |
| 2025-06-05 | Kirk G. Nielsen | Director | A | — | — |
| 2025-06-05 | Kevin J. Ballinger | Director | A | — | — |
| 2025-05-19 | Kirk G. Nielsen | Director | Buy | — | — |
| 2025-05-14 | Kirk G. Nielsen | Director | Buy | — | — |
| 2025-05-13 | Mudit K. Jain | Director | Buy | — | — |
| 2025-05-12 | Kevin Hykes | PRES & CEO | Buy | — | — |
| 2025-03-04 | Robert Allen John | Chief Revenue Officer | A | — | — |
| 2025-03-04 | JARED OASHEIM | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-03-04 | Philip B. Adamson | Chief Medical Officer | A | — | — |
| 2025-03-04 | PAUL VERRASTRO | CHIEF MKTG & STRAT OFFICER | A | — | — |
| 2025-03-04 | Kevin Hykes | PRES & CEO | A | — | — |
| 2024-11-21 | PAUL VERRASTRO | CHIEF MKTG & STRAT OFFICER | MIXED | — | — |
| 2024-09-05 | Mitch C. Hill | Director | A | — | — |
| 2024-09-05 | Kevin J. Ballinger | Director | A | — | — |
| 2024-08-15 | JOSEPH P SLATTERY | Director | Buy | — | — |
| 2024-08-08 | JOSEPH P SLATTERY | Director | Buy | — | — |
| 2024-08-06 | JOSEPH P SLATTERY | Director | Buy | — | — |
| 2024-08-05 | Kevin Hykes | PRES & CEO | Buy | — | — |
| 2024-08-02 | Kevin Hykes | PRES & CEO | A | — | — |
| 2024-07-01 | Robert Allen John | Chief Revenue Officer | A | — | — |
| 2024-06-07 | Kirk G. Nielsen | Director | A | — | — |
| 2024-06-07 | Mudit K. Jain | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,040,861 | — |
| — | 10%+ Owner | 4,024,861 | — |
| — | Director | 1,918,854 | — |
| — | Director | 1,829,022 | — |
| — | 10%+ Owner | 1,800,583 | — |
| — | Director | 994,553 | — |
| — | PRES & CEO | 284,237 | — |
| — | CHIEF FINANCIAL OFFICER | 98,447 | — |
| — | Chief Revenue Officer | 86,036 | — |
| — | Chief Medical Officer | 61,578 | — |
| — | CHIEF MKTG & STRAT OFFICER | 60,551 | — |
| — | 10%+ Owner | 58,175 | — |
| — | CHIEF EXECUTIVE OFFICER | 49,475 | — |
| — | VP OF REG. AFFAIRS AND QA | 43,097 | — |
| — | Director | 39,365 | — |
| — | CHIEF HUMAN RESOURCES OFFICER | 34,000 | — |
| — | 10%+ Owner | 33,316 | — |
| — | CHIEF OPERATING OFFICER | 30,291 | — |
| — | Director | 29,005 | — |
| — | Director | 28,366 | — |
| — | CHIEF STRATEGY OFFICER AND SEC | 21,790 | — |
| — | Director | 8,720 | — |
| — | Director | 8,720 | — |
| — | Director | 8,720 | — |
| — | VP OF GLOBAL CLINICAL RESEARCH | 778 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVRX quote page; the site-wide leaderboard is on the insider transactions hub.